Pediatric mental health provider InStride Health has raised $30 million in Series C funding to accelerate growth and expand its virtual care services across the United States. The funding round was led by new strategic investors Echo Health Ventures and FMZ Ventures, while existing investors including General Catalyst, .406 Ventures, Valtruis, and Mass General Brigham Ventures also participated.
The latest investment highlights growing confidence in InStride’s mission to improve access to specialized mental healthcare for children, teens, and young adults. With this round, the company has now secured $86 million in total funding since its launch in 2021.
Expanding Access to Pediatric Mental Health
Mental health challenges among children and adolescents continue to rise. However, many families struggle to access specialized care due to long wait times, high costs, and limited insurance coverage.
InStride Health aims to solve this problem through an insurance-based virtual care model. The company provides treatment for anxiety, obsessive-compulsive disorder (OCD), and related mental health conditions for patients aged seven to 24 years.
Moreover, the company has rapidly expanded its geographic footprint. InStride now operates in 17 states, primarily across the East Coast and Texas. This marks a significant increase from the eight states it served in 2024. The organization has also treated more than 5,000 patients to date.
Personalized Care Teams
Each patient receives support from a dedicated care team that includes:
- A psychiatrist
- A therapist
- An exposure coach
This multidisciplinary approach allows patients to receive continuous support through video sessions, messaging, and digital tools. In addition, the care team collaborates with parents, schools, and other healthcare providers to create a comprehensive treatment experience.
As a result, children and families receive care that extends beyond traditional clinical settings and becomes part of their daily lives.
The Company’s Evidence-Based Care Model
InStride was founded by Harvard-trained clinicians from McLean Hospital, including Dr. Mona Potter and Dr. Kathryn Boger. They previously developed the McLean Anxiety Mastery Program (MAMP), a program known for delivering strong outcomes for children with anxiety and OCD.
Although the original program achieved impressive results, its limited capacity and self-pay model restricted access. Therefore, the founders launched InStride to bring evidence-based care to more families through insurance-covered virtual services.
Technology and AI Support
InStride combines clinical expertise with technology and AI-powered tools. However, the company emphasizes that AI supports clinicians rather than replacing them.
AI helps the care team by:
- Improving workflows
- Assisting with clinical decision-making
- Identifying patients who are best suited for specific treatment programs
Meanwhile, psychiatrists and therapists continue to lead diagnoses, treatment plans, and patient relationships. This balanced approach allows InStride to scale while maintaining clinical quality.
Growth Across New Markets
The fresh capital will help InStride strengthen its presence in major markets, including:
- Massachusetts
- New York
- Pennsylvania
- New Jersey
- Texas
Furthermore, the company plans to expand into additional East Coast markets and gradually grow its footprint across the Midwest and Western United States over the next year.
This expansion comes at a time when demand for pediatric mental health services is increasing nationwide. Consequently, insurers and investors are looking for scalable solutions that deliver measurable outcomes.
Strong Clinical Outcomes Drive Investor Confidence
InStride’s latest outcomes report demonstrates the effectiveness of its model. According to the company:
- 97% of patients showed clinical improvement
- Anxiety scores declined by an average of 53%
- Less than 1% of patients required hospitalization within 12 months
- 98% of caregivers would recommend InStride to others
- Most patients saw a clinician in less than three days after enrollment
Additionally, 99% of patients used health insurance coverage for treatment. This emphasis on affordability has become one of the company’s strongest differentiators in the competitive digital mental health market.
Why Investors Are Backing InStride
Investors believe InStride addresses one of healthcare’s most urgent challenges: access to specialized pediatric mental health services.
Echo Health Ventures brings deep relationships with Blue Cross and Blue Shield plans, while FMZ Ventures offers expertise in consumer-focused healthcare experiences. Together, these partnerships could help InStride expand payer relationships and improve patient experiences nationwide.
Furthermore, the company’s combination of evidence-based care, insurance coverage, technology, and measurable outcomes positions it well for long-term growth.
Future Outlook
InStride Health’s $30 million Series C funding marks an important milestone in its mission to transform pediatric mental healthcare.
As the company expands into new markets, it plans to maintain its focus on clinical excellence, insurance accessibility, and technology-enabled care. With strong investor backing and proven outcomes, InStride is poised to become a leading force in pediatric mental health services across the United States.
